Physician profile
Navin Kedia
NPI 1457319659
$9,078.54
in general payments reported to CMS, 2019-2025
15 companies · $3,668 in 2025
The $3,668 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,188 · 2020: $774 · 2021: $544 · 2022: $546 · 2023: $560 · 2024: $798 · 2025: $3,668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,194 · Travel and Lodging: $1,833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,193.61 |
| Travel and Lodging | $1,832.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $6,150.50 | 2019-2025 | Ingevity+, General - Therapies, General - Brady |
| Abbott Laboratories | $1,801.47 | 2020-2025 | Aveir, Assurity, Fortify Assura |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $469.47 | 2024-2025 | Lifevest |
| Astellas Pharma US INC | $199.98 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2023 | Jardiance |
| Abiomed | $71.43 | 2025 | |
| Kestra Medical Technology Services, INC. | $71.19 | 2023-2024 | Assure Wcd |
| Medtronic Vascular, INC. | $48.83 | 2020 | |
| Biosense Webster, INC. | $35.68 | 2023 | Carto 3 |
| Elutia, INC. | $21.92 | 2019 | |
| Philips North America LLC | $21.85 | 2020 | |
| Zoll Circulation INC | $17.45 | 2023 | Catheter, Temperature Management System, Temperature Management System Start-Up Kit |
| Inari Medical, INC. | $16.97 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Astrazeneca Pharmaceuticals LP | $13.89 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Navin Kedia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.